An Observational Study to Evaluate Clinical Characteristics of Adult Patients With Suspected or Confirmed Melioidosis

Melioidosis Clinical Trial

Official title:

A Prospective Observational Study to Evaluate Clinical Characteristics, Current Practice and Outcomes of Adult Patients With Suspected or Confirmed Melioidosis

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06089668
• Other study ID #: MEL-OB1
• Status: Recruiting
• Start date: November 1, 2023
• Est. completion date: January 2026

Study information

• Verified date: November 2023
• Source: AN2 Therapeutics, Inc
• Contact: Gabrielle Khedr
• Phone: 650-331-9090
• Email: gkhedr[@]an2therapeutics.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This is a prospective observational study to evaluate clinical characteristics, current practice and outcomes of adult patients (age ≥18 years) with suspected or confirmed melioidosis.

Description:

This is a prospective observational study to evaluate clinical characteristics, current practice and outcomes of adult patients (age ≥18 years) with suspected or confirmed melioidosis. Determination of microbiologically confirmed acute melioidosis among patients presenting with suspected melioidosis, and determination of clinical outcomes of interest (including all-cause mortality, characterization of organ involvement or organ failure, resolution of sepsis, improvement of renal function, rates of suspected vs. microbiologically confirmed melioidosis, and rates of melioidosis involvement of different organ systems) will be performed. Defining clinical and microbiological outcomes in a standardized manner will enable characterization and selection of the relevant outcome measures to be utilized in future clinical studies of IV epetraborole in acute melioidosis. Patients will be identified through daily, active surveillance of hospital admissions at the investigative sites and review of microbiology laboratory culture results. Data will be extracted from hospital and outpatient medical charts. These data will refine the expected treatment effect of standard-of-care antimicrobial therapy and the consequent statistical power calculations needed for sample size and outcome measure design elements of future clinical trials of IV epetraborole adjunctive therapy in hospitalized patients with suspected acute melioidosis.

Participation in the study requires written informed consent from the patient or from their next-of-kin (if needed) at the time of screening. On day 28 (+7) and day 90 (+7) after enrolment the study team will contact the participant by phone interview with standardized script if the participant is discharged alive prior to the day 28 or day 90. There will be no clinical specimens collected as part of the study protocol, as this study aims to observe clinical characteristics and outcomes among patients with confirmed and suspected acute melioidosis in current clinical practice.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 200
• Est. completion date: January 2026
• Est. primary completion date: October 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Males and females 18 years old and greater.

2. Thai and Laos nationality (for study site in Thailand and Laos, respectively).

3. Required hospitalization

4. Community-acquired infection is suspected as the cause of illness (Related terms - e.g. fever, acute fever, community-acquired sepsis, and other infectious diseases [e.g. r/o infectious disease, r/o malaria, r/o dengue, r/o bacteraemia and r/o leptospirosis])

For melioidosis-suspected group ONLY 4a. Community-acquired infection is suspected as the cause of illness (Related terms - e.g. fever, acute fever, community-acquired sepsis, and r/o other infectious diseases [e.g. r/o infectious disease, r/o malaria, r/o dengue, r/o bacteraemia and r/o leptospirosis]) 5a. Hospitalized (at study hospital) for less than 24 hours 6a. Suspected of melioidosis (at least one of the following)

• Ceftazidime or Meropenem has already been prescribed BEFORE screening

• SEPTIC SHOCK (sepsis at screening is defined as SOFA=2 or qSOFA=1; and shock at screening is defined as requiring vasopressor to maintain MAP=65 mmHg)

• SEPSIS (defined as SOFA=2 or qSOFA=1) with AN UNDERLYING DISEASE of diabetes, chronic kidney disease, major thalassemia, cancer or on immunosuppressive drug (including steroid)

For melioidosis-confirmed group ONLY 4b. Have any specimen culture or Immunofluorescence Microscopy (IFM) or Polymerase Chain Reaction (PCR) positive for B. pseudomallei 5b. Patient is still in the study hospital (i.e. alive) on the screening day

Exclusion Criteria:

For Melioidosis-suspected Group ONLY

1. Have confirmed diagnosis of other infectious diseases (e.g. malaria, dengue, leptospirosis) at screening based on rapid diagnostic tests or confirmatory diagnostic tests

2. Non-infectious disease (e.g. stroke, heart attack) is suspected to be a primary cause of the sepsis or shock

3. Hospital-acquired infection is suspected by attending physician as the cause of illness

Related Conditions & MeSH terms

• Melioidosis

Intervention

Other:
• Observational Study
None, this is a non-interventional trial

Locations

Country	Name	City	State
Lao People's Democratic Republic	Mahosot Hospital	Vientiane
Thailand	Srinagarind Hospital	Khon Kaen
Thailand	Sunpasitthiprasong Hospital	Ubon Ratchathani

Sponsors (2)

Lead Sponsor	Collaborator
AN2 Therapeutics, Inc	Mahidol Oxford Tropical Medicine Research Unit

Countries where clinical trial is conducted

Lao People's Democratic Republic,  Thailand, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Data Collection of patients in Thailand with "suspected melioidosis"	Describe, prospective data collection, the presenting clinical characteristics of patients hospitalized in Thailand with "suspected melioidosis" to understand the presentation of this disease in a contemporaneous, rigorously studied cohort.	2 years
Primary	Data Collection of patients in Thailand with "microbiologically confirmed melioidosis ".	Describe, prospective data collection, the presenting clinical characteristics of patients hospitalized in Thailand with "microbiologically confirmed melioidosis " to understand the presentation of this disease in a contemporaneous, rigorously studied cohort.	2 years
Primary	Data Collection of patients in Laos with "suspected melioidosis"	Describe, prospective data collection, the presenting clinical characteristics of patients hospitalized in Laos with "suspected melioidosis" to understand the presentation of this disease in a contemporaneous, rigorously studied cohort.	2 years
Primary	Data Collection of patients in Laos with "microbiologically confirmed melioidosis ".	Describe, prospective data collection, the presenting clinical characteristics of patients hospitalized in Laos with "microbiologically confirmed melioidosis " to understand the presentation of this disease in a contemporaneous, rigorously studied cohort.	2 years
Secondary	Use ± Immunofluorescence Microscopy (IFM) to Determine the percentage of "suspected melioidosis patients" with microbiologically confirmed disease	Use ± IFM to determine the percentage of "suspected melioidosis patients" with microbiologically confirmed disease	2 Years
Secondary	Use ± Polymerase Chain Reaction (PCR) to Determine the percentage of "suspected melioidosis patients" with microbiologically confirmed disease	Use ± PCR to determine the percentage of "suspected melioidosis patients" with microbiologically confirmed disease	2 Years
Secondary	Determine the rates of Burkholderia pseudomallei eradication in patients with microbiologically confirmed acute melioidosis	Determine microbiological eradication patients with microbiologically confirmed acute melioidosis	28 days after enrollment
Secondary	Determine frequency of specific involvement of organ systems involvement in patients with microbiologically confirmed acute melioidosis	Determine the frequency of specific organ system involvement in patients with microbiologically confirmed acute melioidosis	28 days after enrollment
Secondary	Measure rate to resolution of bacteremia conversion to negative cultures	Microbiological outcomes in patients with microbiologically confirmed acute melioidosis	28 days after enrollment
Secondary	Measure time to resolution of bacteremia conversion to negative cultures	Microbiological outcomes in patients with microbiologically confirmed acute melioidosis	28 days after enrollment
Secondary	Frequency of Liver involvement in patients with microbiologically confirmed acute melioidosis (as diagnosed per standard of care)	Frequency of involvement of organ systems in patients with microbiologically confirmed acute melioidosis	28 days after enrollment
Secondary	Frequency of Skin involvement in patients with microbiologically confirmed acute melioidosis (as diagnosed per standard of care)	Frequency of involvement of organ systems in patients with microbiologically confirmed acute melioidosis	28 days after enrollment
Secondary	Frequency of Lung involvement in patients with microbiologically confirmed acute melioidosis (as diagnosed per standard of care)	Frequency of involvement of organ systems in patients with microbiologically confirmed acute melioidosis	28 days after enrollment
Secondary	Frequency of Spleen involvement in patients with microbiologically confirmed acute melioidosis (as diagnosed per standard of care)	Frequency of involvement of organ systems in patients with microbiologically confirmed acute melioidosis	28 days after enrollment
Secondary	Time to resolution of sepsis	Time in days to resolution of sepsis in patients with microbiologically confirmed acute melioidosis who receive antimicrobial therapy directed against B. pseudomallei	enrollment through day 90
Secondary	Time to resolution of fever	Time in days to resolution of fever in patients with microbiologically confirmed acute melioidosis who receive antimicrobial therapy directed against B. pseudomallei	enrollment through day 90
Secondary	Time to resolution of hypotension	Time in days to resolution of hypotension in patients with microbiologically confirmed acute melioidosis who receive antimicrobial therapy directed against B. pseudomallei	enrollment through day 90
Secondary	Determine clinical cure rates among patients with of microbiologically confirmed acute melioidosis who are treated with ceftazidime	Percentage of each clinical outcome of microbiologically confirmed acute melioidosis by antimicrobial treatment regimen	enrollment through day 90
Secondary	Determine clinical cure rates among patients with microbiologically confirmed acute melioidosis who are treated with meropenem	Percentage of each clinical outcome of microbiologically confirmed acute melioidosis by antimicrobial treatment regimen	enrollment through day 90
Secondary	Determine clinical cure rates among patients with suspected melioidosis who are treated with an appropriate antibiotic in the subset of patients with no other microbiologically confirmed diagnosis	Percentage of each clinical outcome of "suspected melioidosis patients" to an appropriate antibiotic (ceftazidime or meropenem) in the subset of patients with no other microbiologically confirmed diagnosis (monomicrobial acute melioidosis)	enrollment through day 90
Secondary	Antimicrobial durations of treatment of microbiologically confirmed acute melioidosis	Antimicrobial durations of treatment of microbiologically confirmed acute melioidosis (including parenteral therapy during the initial phase of treatment and oral therapy during the eradication phase)	enrollment through day 90